Blockade of intra-articular adrenergic receptors increases analgesic demands for pain relief after knee surgery.
Activation of opioid receptors on peripheral sensory nerve terminals by opioid peptides that are produced and released from immune cells can result in inhibition of inflammatory pain. This study tests the hypothesis that postoperative pain is attenuated endogenously through a local sympathetic neurotransmitter-activated release of opioids in patients undergoing knee surgery. We examined the expression of opioid peptides and adrenergic receptors in cells infiltrating inflamed synovial tissue and we hypothesized that intra-articular (i.a.) administration of the adrenergic receptor antagonist labetalol will increase postoperative analgesic consumption and/or pain intensity in these patients. In a double-blind, randomized manner, 75 patients undergoing therapeutic knee arthroscopy received i.a. placebo (20 ml saline) or labetalol (2.5 or 5 mg in 20 ml saline) at the end of surgery. Postoperative pain intensity was assessed by visual analog and verbal rating scales at rest and on exertion, and by the consumption of morphine via patient-controlled analgesia. Synovial biopsies were taken during the operation for double-immunofluorescence confocal microscopy studies. Alpha(1)- and beta(2)-adrenergic receptors were co-expressed in opioid peptide-containing cells. No significant difference was seen in pain scores, but patients receiving 2.5 mg labetalol requested significantly higher amounts of morphine. These findings are consistent with the notion that surgical stress induces sympathetically activated release of endogenous opioids from inflammatory cells and subsequent analgesia via activation of peripheral opioid receptors.
Kager
Ingo
I
Department of Anesthesiology, Landeskrankenhaus Klagenfurt, Klagenfurt, Austria.
Mousa
Shaaban A
SA
Sieper
Joachim
J
Stein
Christoph
C
Pipam
W
W
Likar
Rudolf
R
D058668:Adrenergic alpha-1 Receptor Antagonists / Q000008:administration & dosage / Q000009:adverse effects*; D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000009:adverse effects*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000700:Analgesics / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007270:Injections, Intra-Articular / Q000379:methods; D007718:Knee Injuries / Q000378:metabolism / Q000601:surgery*; D007741:Labetalol / Q000008:administration & dosage / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D010149:Postoperative Pain / Q000188:drug therapy* / Q000378:metabolism; D055815:Young Adult
D058668:Adrenergic alpha-1 Receptor Antagonists; D000319:Adrenergic beta-Antagonists; D000700:Analgesics; D007741:Labetalol
Brain Res Rev. 2009 Apr;60(1):90-113
19150465
Brain Behav Immun. 2002 Dec;16(6):799-807
12480508
Nat Med. 2003 Aug;9(8):1003-8
12894165
J Cardiovasc Pharmacol. 1986 Jan-Feb;8(1):44-50
2419691
Pharmacol Rev. 2000 Dec;52(4):595-638
11121511
Proc Natl Acad Sci U S A. 1999 Jul 6;96(14):7664-7
10393877
Lancet. 1993 Aug 7;342(8867):321-4
8101583
Pharmacol Rev. 2003 Mar;55(1):1-20
12615951
J Neuroimmunol. 2003 Aug;141(1-2):30-9
12965251
Nat Med. 1998 Dec;4(12):1425-8
9846582
Arthritis Rheum. 2000 Sep;43(9):1905-15
11014340
J Rheumatol. 2001 Oct;28(10):2176-83
11669152
Endocrinology. 2004 Mar;145(3):1331-41
14630714
Adv Exp Med Biol. 2003;521:148-60
12617572
J Clin Invest. 1996 Aug 1;98(3):793-9
8698872
Pain. 1999 Dec;83(3):525-532
10568861
J Clin Invest. 2008 Mar;118(3):1065-73
18246198
Br J Anaesth. 2004 Sep;93(3):375-80
15247115
J Rheumatol. 1990 Dec;17(12):1592-9
1707460
J Rheumatol. 2000 Nov;27(11):2558-65
11093434
J Rheumatol. 2002 Mar;29(3):427-35
11908553
Pain. 2002 Aug;98(3):269-275
12127028
Anesth Analg. 1997 Jun;84(6):1313-7
9174312
J Neuroimmunol. 2007 Feb;183(1-2):133-45
17223201
Eur J Neurosci. 2004 Jul;20(1):92-100
15245482
Ann Rheum Dis. 2007 Jul;66(7):871-9
17324971
J Clin Invest. 1997 Jul 1;100(1):142-8
9202066
Anesthesiology. 2004 Jun;100(6):1573-81
15166580
Auton Autacoid Pharmacol. 2002 Feb;22(1):29-35
12423424